Inactive Instrument

Intellipharmaceutics International Inc. Stock Toronto S.E.

IPCI.H

CA4581733090

Valuation: Intellipharmaceutics International Inc.

Market Cap	1.41M 1.24M 1.16M 1.06M 1.99M 135M 2.01M 13.94M 5.41M 68.76M 5.28M 5.17M 223M	P/E 2021	-0.69x	P/E 2022	-0.82x
Enterprise Value	3.65M 3.21M 3.02M 2.76M 5.16M 350M 5.2M 36.17M 14.04M 178M 13.7M 13.4M 579M	EV / Sales 2021	-	EV / Sales 2022	70.4x
Free-Float	98.24%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Press Releases: Intellipharmaceutics International Inc.

17/08/20

Kahn Swick & Foti, LLC : Announces Summary Notice of Proposed Settlement Involving Purchasers of Intellipharmaceutics Common Stock

More press releases

Managers and Directors: Intellipharmaceutics International Inc.

Manager	Title	Age	Since
Amina Odidi DFI	Director of Finance/CFO	-	-
Fazayill Shaideen AUD	Comptroller/Controller/Auditor	-	01/04/2007
Christian Akyempon PRN	Corporate Officer/Principal	-	01/02/2014

Director	Title	Age	Since
Amina Odidi BRD	Director/Board Member	-	01/09/2004

More insiders

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Companyâ€™s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.

Employees

Sector

Pharmaceuticals

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTELLIPHARMACEUTICS INTERNATIONAL INC.	-.--%	-11.11%	-	-	33
ELI LILLY AND COMPANY	+2.68%	+3.87%	+58.22%	+114.68%	1,026B
JOHNSON & JOHNSON	+0.56%	+1.27%	+53.29%	+68.65%	649B
ABBVIE INC.	+0.02%	+0.99%	+19.10%	+73.58%	468B
ROCHE HOLDING AG	+0.06%	+0.25%	+37.03%	+45.71%	352B
NOVARTIS AG	+1.16%	+4.10%	+21.99%	+29.39%	271B
ASTRAZENECA PLC	-0.24%	+2.18%	+10.14%	+12.26%	256B
AMGEN INC.	-0.01%	+7.89%	+41.57%	+51.68%	220B
GILEAD SCIENCES, INC.	-1.11%	+1.36%	+30.85%	+99.56%	188B
NOVO NORDISK A/S	+0.30%	-7.19%	-32.43%	-60.56%	170B
Average	+0.34%	+1.26%	+26.64%	+48.33%	399.9B
Weighted average by Cap.	+0.90%	+1.26%	+37.30%	+67.68%

	2021	2022
Net sales	-	65.73K 57.77K 54.37K 49.75K 92.91K 6.31M 93.74K 652K 253K 3.21M 247K 241K 10.44M
Net income	-5.15M -4.52M -4.26M -3.89M -7.27M -494M -7.34M -51.01M -19.8M -252M -19.32M -18.9M -817M	-2.89M -2.54M -2.39M -2.19M -4.09M -278M -4.12M -28.67M -11.13M -141M -10.86M -10.62M -459M
Net Debt	1.15M 1.01M 947K 867K 1.62M 110M 1.63M 11.36M 4.41M 56M 4.3M 4.21M 182M	2.24M 1.97M 1.85M 1.7M 3.17M 215M 3.2M 22.23M 8.63M 110M 8.42M 8.23M 356M

Intellipharmaceutics International Inc. Stock Toronto S.E.

Stocks

IPCI.H

CA4581733090

Pharmaceuticals

Valuation: Intellipharmaceutics International Inc.

Press Releases: Intellipharmaceutics International Inc.

Managers and Directors: Intellipharmaceutics International Inc.

Other Pharmaceuticals

Financials

Company Profile